Amgen Stock Performance and Analyst Forecasts: A Current Overview

As of Monday, November 25, 2024, Amgen Inc.’s stock closed at $294.00, slightly up from the opening price of $293.98 on the same day. This minor increase reflects the stable performance of the stock in recent trading sessions. On Friday, November 22, 2024, the stock opened at $290.55, marking a 0.23% gain from the previous day’s closing price of $289.88.

Analysts have provided a mixed but generally positive outlook for Amgen stock. The consensus rating is a “buy,” with 32 buy ratings, 22 hold ratings, and 7 sell ratings. The median target price for Amgen stock among 61 analysts is $284.28, with a high estimate of $355.00 and a low estimate of $200.00. This indicates a diverse range of expectations but overall optimism about the stock’s potential.

Historically, Amgen’s stock has seen significant fluctuations. The 52-week low was $260.71, while the 52-week high was $346.67. Currently, the stock is 112.92% away from the 52-week low and 84.92% away from the 52-week high.

Amgen Inc., founded on April 8, 1980, by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld, is a biotechnology company headquartered in Thousand Oaks, CA. The company is engaged in the discovery, development, manufacture, and marketing of human therapeutics, operating through its Human Therapeutics segment.

The company’s market capitalization stands at approximately $154.93 billion, with 537.53 million shares outstanding. Key financial metrics include a dividend yield of 2.96%, a P/E ratio of 23.07, and an EPS of $12.49.